Medpace Holdings (MEDP) IPO Opens Up 22%

Today's IPO for Medpace Holdings (NASDAQ: MEDP) opened for trading at $28.15 after pricing 7,000,000 shares of common stock at a public offering price of $23.00 per share.

Jefferies LLC and Credit Suisse Securities (USA) LLC are acting as joint lead book-running managers for the offering. UBS Securities LLC and Wells Fargo Securities, LLC are also acting as joint book-running managers for the offering. Robert W. Baird & Co. Incorporated and William Blair & Company, L.L.C. are acting as co-managers for the offering.

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its physician-led, high-science, and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,300 people across 35 countries.

You May Also Be Interested In

• Rubrik IPO: 5 key things to know
• Cadence Designs (CDNS) PT Raised to $322 at Baird
• Centuri (CTRI) Opens At $23.75, IPO At $21 (earlier)